Evolution de l'incidence des lymphomes cutanés primitifs en Seine Maritime sur une période de 10 ans

Le but de cette étude était d'évaluer les lymphomes cutanés primitifs en Seine-Maritime sur une période de dix ans. L'étude était rétrospective et réalisée du 01.01.1991 au 01.01.2001. L'identification des lymphomes cutanés a été faite à partir des registres des 11 laboratoires d'anatomopathologie du département (4 laboratoires hospitaliers et 7 laboratoires libéraux). Les comptes rendus et les lames ont été centralisées au CHU. L'ensemble des lames a été relu en insu par le même dermatopathologiste (Ph. C.). L'INSEE nous a fourni les recensements du département des années 1990 et 1999. Le calcul de l'incidence a été fait à l'aide du logiciel Excel ®. La tendance évolutive sur 10 ans a été analysée par régression linéaire. Cent soixante quinze cas de lymphomes ont été identifiés pendant la période de l'étude. Il s'agissait de 117 cas de lymphomes T (67%), de 55 cas de lymphomes B (31%), et de 3 cas de lymphomes non B non T (2%). Il existait une augmentation de l'incidence annuelle, sur 10 ans, des lymphomes cutanés primitifs de phénotype T dans les 2 sexes. L'incidence augmentait chez les hommes pour le MF et chez les femmes pour la papulose lymphomatoïde. Pour les lymphomes cutanés primitifs de phénomène B, l'incidence est restée stable sur dix ans. L'augmentation des lymphomes cutanés T peut être réelle, en dehors de biais de sélection et de recrutement. Ce qui soulève, comme pour les LMNH, l'hypothèse de facteurs environnementaux et viraux.ROUEN-BU Médecine-Pharmacie (765402102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib

International audienc

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

International audienc

Interstitial pneumonia after infliximab therapy for psoriasis

International audienc

Association of occupational exposure with features of systemic sclerosis

International audienceOccupational exposure is reported as playing a substantial causative role in systemic sclerosis (SSc)

Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature

International audienceImmunotherapy has become the standard of care for several types of cancer, such as melanoma. However, it can induce toxicity, including immune checkpoint inhibitor-induced colitis (CIC). CIC shares several clinical, histological, biological, and therapeutic features with inflammatory bowel disease (IBD). Clostridium difficile infection (CDI) can complicate the evolution of IBD. We aimed to characterize the association between CDI and CIC in patients treated with anti-CTLA-4 and anti-PD-1 for melanoma. Patients from nine centers treated with anti-CTLA-4 and anti-PD-1 for melanoma and presenting with CDI from 2010 to 2021 were included in this retrospective cohort. The primary endpoint was the occurrence of CIC. The secondary endpoints were findings allowing us to characterize CDI. Eighteen patients were included. Eleven were treated with anti-PD-1, four with anti-CTLA-4, and three with anti-PD-1 in combination with anti-CTLA-4. Among the 18 patients, six had isolated CDI and 12 had CIC and CDI. Among these 12 patients, eight had CIC complicated by CDI, three had concurrent CIC and CDI, and one had CDI followed by CIC. CDI was fulminant in three patients. Endoscopic and histological features did not specifically differentiate CDI from CIC. Nine of 11 patients required immunosuppressive therapy when CDI was associated with CIC. In nine cases, immunotherapy was discontinued due to digestive toxicity. CDI can be isolated or can complicate or reveal CIC. CDI in patients treated with immunotherapy shares many characteristics with CDI complicating IBD. Stool tests for Clostridium difficile should be carried out for all patients with diarrhea who are being treated with immunotherapy

Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort

International audienc

A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type

International audienc